Authors

Ivo Abraham, PhD

Ivo Abraham is chief scientist of Matrix45 and professor of pharmacy, medicine, and clinical translational sciences at the University of Arizona, where he is associated with the Center for Health Outcomes and PharmacoEconomic Research. He has worked in biologic drugs since the late 1990s and in biosimilars since their introduction in the European marketplace – collaborating closely with Karen MacDonald, who is also his wife. On both the private and academic sides, his group published the first economic evaluations of biosimilars, a line of studies that continues to date. Building on large international observational studies on biological therapies that the Abraham-MacDonald tandem implemented in the late 1990s and early 2000s, they worked with Sandoz on the MONITOR-GCSF and MONITOR-CKD-5 studies that proved to be instrumental in the breakthrough of biosimilars in Europe. As biosimilars entered the US market, Matrix45 added studies in support of biosimilar adoption in the United States. More recently, Matrix45 has ventured into biosimilars in emerging markets, including low- and middle-income countries. He may be reached at

Mike Gladstone

Mike Gladstone is the global president of Inflammation and Immunology at Pfizer.

Jeff Patton, MD

Jeff Patton, MD, is a board-certified hematologist and oncologist, CEO and board member at OneOncology, where he also served as president of physician services for over a year.

Robert Popovian, PharmD, MS

Chief Science Policy Officer, GHLF, Senior Health Policy Fellow, PPI and Visiting Health Policy Fellow, Pioneer Institute

Laura Joszt

Laura is the editorial director of The American Journal of Managed Care

Rebecca Clegg, JD

Rebecca Clegg is an associate in Axinn’s Intellectual Property group. Her practice focuses on complex intellectual property litigation and counseling, in the fields of medical devices, pharmaceuticals and biotechnology.

Drew Hillier JD

Drew Hillier is an associate with

Helen H. Ji

Helen H. Ji is an associate intellectual property attorney at

Ted Mathias, JD

Ted Mathias focuses on trying patent cases. In the last 2 years, he tried 2 cases to judgment and served as lead counsel in a case involving 33 patents that settled favorably on the eve of trial. Mathias has litigated patent cases and handled successful appeals to the Federal Circuit in the areas of medical devices, pharmaceuticals, mechanical devices, e-commerce and software.

Kevin M. Nelson

Kevin M. Nelson is an intellectual property attorney